Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Cost of Captisol | 3,214 | 2,907 | 6,487 | 7,756 |
| Amortization of intangibles | 8,097 | 8,258 | 16,194 | 16,515 |
| Research and development | 14,668 | 6,567 | 16,816 | 56,652 |
| General and administrative | 29,123 | 20,175 | 49,959 | 38,976 |
| Fair value adjustments to partner program derivatives | — | 1,276 | — | 833 |
| Total operating costs and expenses | 55,102 | 39,183 | 89,456 | 120,732 |
| Operating income (loss) | 8,591 | 8,444 | 25,959 | (27,772) |
| Non-operating income and expenses: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's G&A?
- Ligand Pharmaceuticals (LGND) reported G&A of $29.12M in Q2 2026.
- How has Ligand Pharmaceuticals's G&A changed year-over-year?
- Ligand Pharmaceuticals's G&A increased by 44.4% year-over-year, from $20.18M to $29.12M.
- What is the long-term trend for Ligand Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's G&A has grown at a 18.6% compound annual growth rate (CAGR), from $46.79M to $92.45M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Ligand Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude